On May 30, 2019 Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory, cancer and other diseases, reported that Stephen Yoder, President and Chief Executive Officer of Pieris Pharmaceuticals, Inc., will present at the Jefferies 2019 Healthcare Conference in New York, New York on Thursday, June 6, 2019 at 3:30 PM (EDT) (Press release, Pieris Pharmaceuticals, MAY 30, 2019, View Source [SID1234536701]). A webcast of the company’s presentation will be available at this link.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 30, 2019 OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic prostate cancer vaccine immunotherapy and a CD71-targeted cancer therapy combining paclitaxel, gallium, and transferrin, otherwise known as PGT, reported the results of initial in vitro data for PGT in a Multi-drug resistant ovarian cancer model (Press release, Oncbiomune, MAY 30, 2019, View Source [SID1234536719]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cell proliferation assays were performed on 2 cell lines, MCF-7 (a breast cancer cell line known to be sensitive to chemotherapy) and NCI/ADR-RES (OVCAR-8 ADR-RES, a multidrug-resistant cell line that is a model for the study of drug resistance in ovarian cancer) grown under hypoxic conditions and treated separately with varying concentrations of either the standard chemotherapy agent paclitaxel or PGT for 72 hours. The IC50 (concentration of drug needed to inhibit the cell growth by 50%) was determined for paclitaxel and PGT, standardized by the concentration of paclitaxel. The IC50s were calculated from growth inhibition curves.

The IC50s for the MCF-7 cells were similar for paclitaxel and PGT (range 0.02 to 0.09 micromolar). However, the IC50 of the NCI/ADR-RES cells for the paclitaxel was 216 micromolar and the IC50 for the PGT was 0.0318 micromolar. This shows that in this experiment, a 6797-fold decrease in the concentration of PGT can obtain the same inhibition of cancer cell growth as the standard chemotherapy paclitaxel in this multidrug-resistant model. Additionally, this concentration of PGT is similar to the IC50 of paclitaxel seen in the chemotherapy sensitive MCF-7 cells. Taken together, this implies that PGT is able to overcome drug resistance mechanisms at play in the NCI/ADR-RES cell line model of chemotherapy resistance and thereby makes these cells sensitive to PGT therapy in an acceptable concentration range.

PGT is designed to deliver the chemotherapeutic agent paclitaxel to cancer cells over-expressing the transferrin receptor (aka CD71). Paclitaxel is currently FDA-approved in two forms: as solvent-based paclitaxel (sb-paclitaxel, Taxol) and protein-based paclitaxel (nab-paclitaxel, ABRAXANE ).

PGT combines paclitaxel to the human protein transferrin as opposed to albumin, which is employed in nab-paclitaxel. This creates the potential to target the paclitaxel to CD71, which has been shown to be highly over-expressed on many different types of cancer cells.

Additionally, PGT takes advantage of the fact that the transferrin protein has binding sites for iron that can also bind gallium, which has anti-cancer activity. In theory, this creates a novel protein drug complex which has the capacity to deliver two, non-cross resistant cancer therapeutics in a targeted fashion.

"This is only one experimental model, but it does suggest that PGT has the potential to show activity in cancer cells that are resistant to standard chemotherapies that are used widely in patients today," commented Dr. Brian Barnett, Chief Executive Officer at OncBioMune. "This experiment utilizes a well characterized ovarian cancer cell line that is multi-drug resistant. In the near future, we plan to perform tests on other models as we are hopeful that this therapy may show broad activity in multiple cancer types with the ultimate goal of developing PGT for patients with refractory cancers, an area of high unmet medical need."

On May 30, 2019 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, reported that Utpal Koppikar, the Company’s Chief Financial Officer, will participate at two upcoming investor conferences in June (Press release, Atara Biotherapeutics, MAY 30, 2019, View Source [SID1234536686]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies 2019 Global Healthcare Conference
Company Presentation: Wednesday, June 5, 2019 at 8:30 a.m. EDT
Grand Hyatt in New York, NY

Goldman Sachs 40th Annual Global Healthcare Conference
Fireside Chat: Thursday, June 13, 2019 at 10:00 a.m. PDT
Terranea Resort in Rancho Palos Verdes, CA

Live audio webcasts of the presentation and fireside chat will be available by visiting the Investor Events and Presentations section of atarabio.com. Archived replays will be available on the Company’s website for approximately 14 days following the live webcasts.

On May 30, 2019 TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, and through our license to Santen Pharmaceutical Co. Ltd., wet age‐related macular degeneration, reported that Charles Theuer, M.D., Ph.D., President and CEO, will present a corporate overview at the Jefferies 2019 Healthcare Conference at 2:30 pm EDT on Friday, June 7, 2019, in New York, NY (Press release, Tracon Pharmaceuticals, MAY 30, 2019, View Source [SID1234536702]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access a live webcast of the presentation, please visit the "Events and Presentations" page within the "Investors" section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.

On May 30, 2019 Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, reported that it will present data and exhibit at the 2019 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 31 to June 4, 2019, at the McCormick Place Convention Center in Chicago, Illinois (Press release, Athenex, MAY 30, 2019, View Source;p=RssLanding&cat=news&id=2400079 [SID1234536687]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Athenex will introduce its new brand established for the oncology platform, Athenex Oncology, at its exhibition booth (#4150) at ASCO (Free ASCO Whitepaper) 2019 (exhibition dates: June 1 to 3, 2019), which will also showcase the potential of the Orascovery Platform and latest development pipeline.

Athenex has four abstracts accepted for poster presentation and two abstracts accepted for online publication only.

Details of Poster Presentations:

Title: (Abstract TPS1116) KX-ORAX-001: An open label, randomized, multicenter, Phase III registrational study to determine the safety, tolerability, and tumor response of Oraxol (HM30181A + oral paclitaxel) and its comparability to IV paclitaxel in patients with metastatic breast cancer (MBC).
Presenter: Gerardo Antonio Umanzor Funez, DEMEDICA, San Pedro Sula, Honduras
Poster Session: Breast Cancer—Metastatic
Session Date, Time, Location: Sunday, June 2, 2019, 8:00 AM-11:00 AM Central Daylight Time, Hall A
The abstract is available on the ASCO (Free ASCO Whitepaper) website here.

Title: (Abstract 1084) Oral paclitaxel in the treatment of metastatic breast cancer (MBC) patients.
Presenter: Ming-Shen Dai, Tri-Service General Hospital, Taipei, Taiwan
Poster Session: Breast Cancer—Metastatic
Session Date, Time, Location: Sunday, June 2, 2019, 8:00 AM-11:00 AM Central Daylight Time, Hall A
The abstract is available on the ASCO (Free ASCO Whitepaper) website here.

Title: (Abstract 3032) A Phase 1 study of the oral administration of irinotecan in combination with the potent P-glycoprotein (P-gp) inhibitor HM30181A.
Presenter: Antonio Jimeno, University of Colorado, Aurora, CO
Poster Session: Developmental Therapeutics and Tumor Biology (Nonimmuno)
Session Date, Time, Location: Saturday, June 1, 2019, 8:00 AM-11:00 AM Central Daylight Time, Hall A
The abstract is available on the ASCO (Free ASCO Whitepaper) website here.

Title: (Abstract 3090) Design, engineering, and characterization of a novel long-acting (Pegylated) single isomer human arginase for arginine depriving anti-cancer treatment.
Presenter: Kuo-Ming Yu, Athenex, Inc., Buffalo, NY
Poster Session: Developmental Therapeutics and Tumor Biology (Nonimmuno)
Session Date, Time, Location: Saturday, June 1, 2019, 8:00 AM-11:00 AM Central Daylight Time, Hall A
The abstract is available on the ASCO (Free ASCO Whitepaper) website here.

Abstracts Accepted for Online Publication Only:

Title: (Abstract e15518) A phase Ib study of oraxol in combination with ramucirumab in patients with gastric or esophageal cancers who failed previous chemotherapy.
The abstract is available on the ASCO (Free ASCO Whitepaper) website here.

Title: (Abstract e12577) Eribulin ORA: A novel oral formulation of eribulin based on combination with
the P-gp inhibitor HM30181A.
The abstract is available on the ASCO (Free ASCO Whitepaper) website here.

The Orascovery platform was initially developed by Hanmi Pharmaceuticals and licensed exclusively to Athenex for all major worldwide territories except Korea, which is retained by Hanmi.

About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived from four different platform technologies: (1) Orascovery